Now in its 13th year, Drug Discovery 2019, ELRIG’s flagship conference, will take place at the ACC in Liverpool on the 5-6th November. The conference is one of the largest meetings of life science industry professionals in the UK.
The focus of this year’s event is ‘A Look Back to the Future’ which will examine how we got to where we are now and what the challenges will be for the future of drug discovery.
The event will feature over 40 world-class speakers including Dr Mene Pangalos from AstraZeneca and Dr Fiona Marshall from MSD.
TherapeutAix participated last year, when the conference focused on ‘Drug Discovery for Small & Large Molecules’. The team presented a poster on advancing assets in drug discovery, which showcased a case study on progressing compounds in idiopathic pulmonary fibrosis.
This year, TherapeutAix will be delivering a joint oral presentation with the Medicines Discovery Catapult titled ‘Biomarker Strategies in Drug Discovery: Can we Reduce Attrition and Streamline Development of Novel Anti-Fibrotics?’. The session aim is to discuss how appropriate, well validated, biomarkers will drive a reduction in drug attrition in all therapeutic areas over the next few decades.
We look forward to catching up with our clients and contacts and hearing the latest insights from across academia, biotech and the pharma industry.
To find out more about the conference and view the online programme, please click here.